A Retrospective Real-World Cohort Study

Sponsor
Novo Nordisk A/S
Study ID
NCT07781371
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cardiovascular Disease (CVD)
  • Chronic Kidney Disease (CKD)
  • Dyslipidemia
  • Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
  • Obesity
  • Prediabetes
  • Type 2 Diabetes (T2D)

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • No treatment given — OTHER
    No treatment given

Study Details

The primary objectives are to determine the prevalence and overlap of major cardiometabolic diseases, identify multimorbidity clusters, and characterize demographic, clinical, laboratory, and treatment patterns across the cohort and relevant subgroups. This study is based on anonymized electronic health record (EHR) data and spanning January 2022 to December 2025. EHR will be extracted from participants of Acibadem hospital network in Turkey. Participants received routine clinical care according to physician discretion. Index date will be defined by the first diagnosis of cardiometabolic conditions. Follow-up period will include at least one year of to allow description of long-term outcomes. It will extend until the end of study, last recorded encounter, or death.

Key Dates

First listed
Aug 24, 2026
Start date
Aug 20, 2026
Status verified
Aug 2026
Primary completion
Nov 2, 2026
Completion
Nov 2, 2026

Study Design

Enrollment
100,000 participants (estimated)

Arms

  • Arm: SCALA cohort
    Participants from Acibadem hospital network in Türkiye with index date followed by at least one year of follow-up and the data extraction period spanning from 1 January 2022 to 31 December 2025.

Primary Outcome Measure

Index and yearly prevalence of major cardiometabolic diseases (percentage) [ Time Frame: Baseline (at index date i.e., between 1 January 2022 to 31 December 2025), and at the end of each calendar year ]

Central Contacts

Find similar trials

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies